MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Device-aided Therapies are Associated with Significantly Greater Improvement in Quality of Life in Younger Patients Earlier Within Advanced Parkinson’s Disease

    D. Santos García, á. Solleiro Vidal, L. López Manzanares, S. Martí Matínez, J. González Ardura, J. Gómez Esteban, T. Delgado, G. González Ortega, E. Cubo, B. Solano, AB. Perona-Moratalla, S. Escalante, á. Monterde Ortega, MP. Gil Martín, R. López Blanco, C. Borrué Fernández, I. Martínez Torres, P. García Ruíz, I. Pareés Moreno, C. Delgado Suárez (A Coruña, Spain)

    Objective: To evaluate the impact on health-related quality of life (HRQoL) of treatment with device-aided therapies (DAT) in younger patients earlier within advanced Parkinson's disease…
  • 2026 International Congress

    The Effect of LRRK2 and GBA1 Mutations on Survival in Early- and Late-onset Parkinson’s Disease

    R. Rubin, RN. Alcalay, N. Omer, O. Goldstein, M. Gana Weisz, A. Mirelman, A. Thaler (Tel Aviv, Israel)

    Objective: Survival assessment of PD patients genetically tested at Tel-Aviv Sourasky Medical Center between 2005-2025. We hypothesize that LRRK2-PD would show higher survival rates compared…
  • 2026 International Congress

    Intravenous AAVrh.10hFXN (LX2006) Gene Therapy in Friedreich Ataxia: Early Neurologic Assessment from Two Phase 1 and 2 Studies

    T. Zesiewicz, T. Vu, J. Weinsalft, S. Kaminsky, A. Patel, R. Gavrilova, S. Perlman, U. Krishnan, M. Galbraith, N. Savage, R. Kaner, M. Vo, H. Sarva, A. Yoo, D. Sondhi, C. Rummey, G. Aubert, A. Khan, S. Ghanekar, R. Crystal (Tampa, USA)

    Objective: To evaluate neurologic measures of efficacy of intravenous AAVrh.10hFXN (LX2006) gene therapy in adults with Friedreich ataxia, based on data from the SUNRISE-FA study…
  • 2026 International Congress

    Does Balance Mediate the Relationship Between Aerobic Capacity and Walking Endurance in Parkinson’s Disease?

    C. Balasubramaniam, I. Wilkinson, J. Osborne, K. Flanagan, K. Mangipudi (Jacksonville, USA)

    Objective: To examine whether balance mediates the relationship between aerobic capacity and walking endurance in individuals with Parkinson’s disease (PD) Background: Impaired walking capacity contributes…
  • 2026 International Congress

    Sex differences for clinical impact of APOEe4 mediated by Alzheimer’s pathology in people with Lewy body pathology

    E. Bayram, B. Bettcher, S. Holden (Aurora, USA)

    Objective: Assess whether Alzheimer’s (AD) or Lewy body (LB) pathologies mediate the association between APOEe4 and clinical profile differently for females and males with LB…
  • 2026 International Congress

    Digital cognitive training and promoting a healthy lifestyle as a booster for cognitive reserve in prodromal Parkinson’s disease?

    A. Ophey, S. Röttgen, K. Kufer, J. Pauquet, D. Scharfenberg, P. Armbrust, A. Kammerzell, N. Knopf, S. Kollath, P. Sommer, CEJ. Doppler, E. Farrher, A. Seger, NJ. Shah, D. Zopfs, K. Reetz, GR. Fink, M. Sommerauer, E. Kalbe (Cologne, Germany)

    Objective: To investigate predictors of responsiveness to a multimodal cognitive training intervention in individuals with isolated REM sleep behavior disorder (iRBD). Background: The prodromal phase…
  • 2026 International Congress

    Efficacy of Opicapone in Early Motor Fluctuations in Parkinson’s Disease: A Comparison of Early versus Later Initiation

    JJ. Ferreira, F. Stocchi, A. Antonini, O. Rascol, G. Ebersbach, J. Kulisevsky, MM. Fonseca, D. Ramos, J-F. Rocha, HC. Brigas, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: This post-hoc analysis assessed the long-term outcomes of early initiation of opicapone in levodopa-treated patients with early wearing-off in Parkinson’s disease. Background: The best…
  • 2026 International Congress

    The Anxiolytic Effect of Cannabidiol and Tetrahydrocannabinol in a Reserpine Model of Parkinson’s Disease in Mice

    H. Tanko, T. Muhammad, A-S. Isa (Zaria, Nigeria)

    Objective: This study evaluated the anxiolytic effects of CBD, THC, and their combination in a reserpine-induced Parkinson’s mouse model using the Elevated Plus Maze (EPM)…
  • 2026 International Congress

    Cognitive Impairment and Neuropsychiatric Manifestations in Parkinson’s disease in Africa: A Systematic Review of Evidence

    M. Njohjam, F. Niakam, M. Ngoule (Dakar, Senegal)

    Objective: To critically appraise and synthesize evidence on the prevalence and clinical correlates of cognitive impairment and neuropsychiatric manifestations among patients with Parkinson’s disease in…
  • 2026 International Congress

    Investigating Substantia Nigra Microstructural Integrity as a Potential Predictive Biomarker for Fall Burden in Parkinson’s Disease

    I. Bedoy, J. Tejeda, R. Rajmohan, N. Phielipp (Irvine, USA)

    Objective: Determine whether baseline Diffusion Tensor Imaging (DTI) measures of the substantia nigra (SN) predict fall incidence and burden in Parkinson’s disease (PD). Background: Degeneration of dopaminergic…
  • « Previous Page
  • 1
  • …
  • 89
  • 90
  • 91
  • 92
  • 93
  • …
  • 208
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley